TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14578410
Drug: Lomerizine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomerizine 0.3 mg/kg
Study: 14578410
Drug: Lomerizine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomerizine 5 mg
Study: 8279682
Drug: Weak ultrasonication
Normalized name: weakleaf bur ragweed pollen extract
DrugBank: Ambrosia confertiflora pollen (DB10872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weak ultrasonication of ethanol solutions (40 kHz, 12 mW, 1 week)
Study: 8279682
Drug: Treated aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated aqueous ethanol solution
Study: 8279682
Drug: Treated solutions
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treated solutions
Study: 2881574
Drug: Org 2305
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 2305 15 mg (O 15)
Study: 2881574
Drug: Org 2305
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 2305 30 mg (O 30)
Study: 2881574
Drug: Org 2305
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 2305 60 mg (O 60)
Study: 2881574
Drug: Diazepam 15
Normalized name: diazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 15 mg (DZ)
Study: 18463885
Drug: Treatment started
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment started within the first hour after AAT (Group A, 20 patients)
Study: 18463885
Drug: Treatment started
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment started more than 1 hour later and less than 16 hours after AAT (Group B, 17 patients)
Study: 18463885
Drug: Treatment started
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment started after 24 hours or more (Group C, 15 patients)
Study: 16612257
Drug: Enalapril administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril administration for 3 days
Study: 30066385
Drug: Nicotine pre-loading
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine pre-loading (4 weeks of 21 mg nicotine patch use prior to quitting)
Study: 30066385
Drug: Standard smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard smoking cessation medications with behavioral support
Study: 27213492
Drug: Mindfulness‐Based Addiction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness‐Based Addiction Treatment (MBAT)
Study: 25265494
Drug: vemurafenib and
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vemurafenib and cobimetinib (combination group)
Study: 10517693
Drug: 0.05% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% betamethasone 17-21 dipropionate lotion (Diprosone lotion)
Study: 7747540
Drug: Oral cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporin 5 mg/kg/day
Study: 7747540
Drug: Topical dithranol
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dithranol and ultraviolet B therapy
Study: 3083829
Drug: Ranitidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (2 X 150 mg/d)
Study: 3083829
Drug: Omeprazole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (5 mg and 10 mg/d)
Study: 3083829
Drug: Ranitidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (2 X 25 mg/d)
Study: 25135997
Drug: Rituximab treatment
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab treatment with vitamin D levels ≤ 8 ng/mL
Study: 25135997
Drug: Rituximab treatment
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab treatment with vitamin D levels > 8 ng/mL
Study: 25135997
Drug: Rituximab treatment
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab treatment without vitamin D deficiency (levels ≤ 8 ng/mL or > 8 ng/mL)
Study: 27206943
Drug: Ezetimibe (EZE)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (EZE) 10 mg
Study: 15924587
Drug: Ezetimibe (EZE)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (EZE) co-administered with atorvastatin (ATV)
Study: 31168711
Drug: Eight sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight sessions of moderate intensity aerobic exercise along with eight self-management modules during chemotherapy.
Study: 29683702
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy (PE) alone
Study: 29683702
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy (PE) + alcohol use disorder treatment
Study: 29683702
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy (PE) + nicotine use disorder treatment
Study: 16263773
Drug: 480 micromol
Normalized name: BENZALKONIUM CHLORIDE 0.3068 g in 236 mL TOPICAL SOAP [MicroGold Anti-Bacterial Waterless Hand (4 oz.)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 micromol x kg(‐1) x h(‐1) intravenous amino acid solution for 5 h
Study: 16263773
Drug: 960 micromol
Normalized name: BENZALKONIUM CHLORIDE 0.3068 g in 236 mL TOPICAL SOAP [MicroGold Anti-Bacterial Waterless Hand (4 oz.)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 960 micromol x kg(‐1) x h(‐1) intravenous amino acid solution for 5 h
Study: 16263773
Drug: 960 micromol
Normalized name: BENZALKONIUM CHLORIDE 0.3068 g in 236 mL TOPICAL SOAP [MicroGold Anti-Bacterial Waterless Hand (4 oz.)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 960 micromol x kg(‐1) x h(‐1) intravenous amino acid solution for 24 h
Study: 8299406
Drug: EDTA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA treatment (20 repeated infusions of 3 grams over 5-9 weeks)
Study: 27267753
Drug: MEDI-551 (0.1-10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-551 (0.1-10.0 mg/kg)
Study: 19024525
Drug: Domestic docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Domestic docetaxel (70 mg/m2 on D2) combined with doxorubicin (40 mg/m2 on D1)
Study: 19024525
Drug: Taxotere (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxotere (70 mg/m2 on D2) combined with doxorubicin (40 mg/m2 on D1)
Study: 10547170
Drug: Pharmacist-initiated interventions
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmacist-initiated interventions involving anti-infective agents
Study: 8975568
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of opiate premedication, regional blocking, and parenteral diclophenak-Na before and after the operation
Study: 31689890
Drug: Iodine supplementation
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine supplementation (225 ug/day, potassium iodide tablets)
Study: 25146513
Drug: Fluvastatin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin IR 40 mg twice daily
Study: 12693793
Drug: Once-daily budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily budesonide/formoterol (160/4.5 microg, two inhalations)
Study: 12693793
Drug: Twice-daily budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily budesonide/formoterol (160/4.5 microg, one inhalation)
Study: 12693793
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 microg) once-daily
Study: 10711617
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine solution rinsed twice during 4 hours
Study: 10711617
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine solution rinsed three times during 24 hours
Study: 3903382
Drug: Flatoril (dimethicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flatoril (dimethicone 200 mg and clebopride 0.5 mg)
Study: 27918968
Drug: Web-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cognitive behavioral therapy with asynchronous therapeutic support
Study: 23492647
Drug: ARB+C (amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB+C (amlodipine 5mg + typical dosage of ARBs)
Study: 22227229
Drug: mpHBV (modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: mpHBV (modified process hepatitis B vaccine)
Study: 18690015
Drug: RECOMBIVAX HB
Normalized name: Recombivax HB
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RECOMBIVAX HB (control vaccine)
Study: 18690015
Drug: mpHBV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: mpHBV and RECOMBIVAX HB (control vaccine)
Study: 16957573
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg/day for 3 months
Study: 16957573
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment change)
Study: 11097593
Drug: Topical proparacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical proparacaine hydrochloride 0.5%
Study: 11097593
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to oleoresin capsicum (pepper spray)
Study: 9024449
Drug: CRP-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP-guided treatment (group 1)
Study: 9024449
Drug: CRP-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP-guided treatment (group 2a)
Study: 9024449
Drug: At least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least 5-day treatment (group 2b)
Study: 1332213
Drug: Fragmin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmin administered subcutaneously once daily (200 U(anti‐FXa)/kg/24h)
Study: 1332213
Drug: Fragmin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmin administered subcutaneously twice daily (100 U(anti‐FXa)/kg/12h)
Study: 22169794
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily and Sorafenib 400 mg twice daily (MTD)
Study: 18684771
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (NTG) 500 microg
Study: 18684771
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (NTG) 375 microg
Study: 18684771
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (NTG) 250 microg
Study: 17313008
Drug: Shu‐Mu point
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shu‐Mu point combination
Study: 17313008
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Danazol)
Study: 10721508
Drug: Manual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual physical therapy combined with supervised exercise
Study: 8936356
Drug: ORG 2766
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 2766 0.1 mg
Study: 8936356
Drug: ORG 2766
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 2766 0.4 mg
Study: 8936356
Drug: ORG 2766
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 2766 2 mg
Study: 6388715
Drug: Ornithine-8-vasopressin injection
Normalized name: Vasopressin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornithine-8-vasopressin injection
Study: 20488250
Drug: Usual exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual exercise therapy (UC; usual care)
Study: 12776579
Drug: DHEP formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEP formulation with lecithin
Study: 12776579
Drug: Marketed DHEP
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed DHEP formulation without lecithin
Study: 1673937
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole 1.0 g
Study: 7323709
Drug: 5 MIU
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 MIU of penicillin intravenously twice daily for 4 days, plus intraincisional injection of penicillin at wound closure
Study: 7323709
Drug: 2 MIU
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 MIU penicillin and 0.5 g streptomycin twice daily for 5 days (control group)
Study: 6366769
Drug: Penicillin therapy
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin therapy
Study: 8078529
Drug: Budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg daily
Study: 8078529
Drug: Budesonide 15
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 15 mg daily
Study: 2462341
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (encainide, flecainide, moricizine, imipramine)
Study: 55647
Drug: B.C.G. treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: B.C.G. treatment
Study: 55647
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no B.C.G.)
Study: 31707805
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg od plus single antiplatelet therapy (SAPT)
Study: 31707805
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg bid plus dual antiplatelet therapy (DAPT)
Study: 31707805
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus DAPT
Study: 28109423
Drug: Policy proposals
Normalized name: Polivy
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Policy proposals to restrict SNAP benefits based on nutrition quality (e.g., excluding sugary drinks)
Study: 23990895
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) consisting of 12 weekly sessions of either cognitive therapy (n=41) or prolonged exposure (PE, n=49), starting 29.8±5.7 days after ED admission
Study: 21831508
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg p.o. three times daily)
Study: 21831508
Drug: N-acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine (NAC) (600 mg p.o. three times daily)
Study: 11788129
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate treatment
Study: 9750032
Drug: 2 years
Normalized name: Childrens Panadol 5 - 12 Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 years of daily uracil/tegafur (UFT)
Study: 3284310
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (MEX-Q)
Study: 3284310
Drug: Drug free
Normalized name: Tenscare Pain Aide Drug Free Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug free
Study: 26959668
Drug: Telephone-based problem-solving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based problem-solving treatment (PST)
Study: 24176498
Drug: Tritanrix HB+Hib
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tritanrix HB+Hib (first dose) and Quinvaxem (second/third doses)
Study: 24176498
Drug: Quinvaxem (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinvaxem (three doses)
Study: 20529401
Drug: MM supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: MM supplement with improved gruel (MMGG)
Study: 3033751
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment radiotherapy and polychemotherapy (C.A.P. + V.D.S.)
Study: 3033751
Drug: Split‐dose irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split‐dose irradiation alone
Study: 29415891
Drug: gmDC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: gmDC treatment (23 patients)
Study: 29415891
Drug: gmDC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gmDC vaccine (12 acute myeloid leukemia patients)
Study: 29415891
Drug: Standard donor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard donor lymphocyte infusion (25 patients)
Study: 29415891
Drug: gmDC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: gmDC treatment (35 patients total)
Study: 23589106
Drug: Vaccination in
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination in combination with MDSC targeted therapy with all‐trans‐retinoic acid (ATRA) (Arm C)
Study: 20608293
Drug: Rotation-oscillation 'On'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotation-oscillation 'On' (Oral-B Triumph with FlossAction brush head)
Study: 18855824
Drug: Cocaine self-administration
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine self-administration sessions (randomized, placebo-controlled)
Study: 14675918
Drug: High-risk features
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk features (T-PSA >10 ng/ml or Gleason sum >=7)
Study: 10973768
Drug: Trimetazidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (40 mg intravenous bolus followed by 60 mg continuous infusion for 48 hours)
Study: 8827741
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.75 mg.kg‐1
Study: 25313065
Drug: Sulforaphane (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulforaphane (50-150 µmol daily for 18 weeks)
Study: 18721251
Drug: Pilocarpine/timolol maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine/timolol maleate fixed combination (PTFC) given twice daily
Study: 17133211
Drug: MK-0518 100
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0518 100 mg
Study: 17133211
Drug: MK-0518 200
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0518 200 mg
Study: 17133211
Drug: MK-0518 400
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0518 400 mg
Study: 17133211
Drug: MK-0518 600
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0518 600 mg
Study: 10698133
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (75 mg/kg, maximum 2 g)
Study: 10698133
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg/kg, maximum 10 mg)
Study: 24091718
Drug: Depression treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depression treatment
Study: 22241604
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of laboratory‐expanded, skin‐derived fibroblasts suspended in autologous plasma
Study: 22241604
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection of local anesthetic and physiotherapy
Study: 20531220
Drug: Lamotrigine (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (dosing ranged from 12.5 to 300 mg/d)
Study: 8824694
Drug: Acute propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute propranolol (0.15 mg kg‐1 i.v.)
Study: 8824694
Drug: Chronic propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic propranolol (80 mg three times daily for 2 weeks)
Study: 28031053
Drug: Golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 50 mg or 100 mg injections every 4 weeks through week 24
Study: 28031053
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections every 4 weeks through week 24
Study: 25910610
Drug: High uterosacral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High uterosacral vault suspension (HUVS)
Study: 19117152
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg bupivacaine
Study: 9201844
Drug: Premarin, 1
Normalized name: Premarin, 1.25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin, 1 mg/kg intravenously in the immediate postoperative period
Study: 1492408
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of evening primrose oil and fish oil (GLA, EPA, DHA)
Study: 30701988
Drug: Sunitinib (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (37.5 mg on a continuous daily‐dosing regimen)
Study: 26956689
Drug: Adjuvant XELOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant XELOX (capecitabine plus oxaliplatin); capecitabine 1000 mg/m2 twice daily on days 1-14, oxaliplatin 130 mg/m2 on day 1 for eight 3-week cycles
Study: 20980493
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg folic acid/d
Study: 20980493
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg folic acid/d